AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated October 11, 2025.
Gilead Sciences is a biopharmaceutical company primarily focused on antiviral drugs used in the treatment of HIV, Hepatitis B, and Influenza, among other diseases. With a history of strong drug portfolio performance, the company commands significant market share in the antiviral segment. Known for its innovation and robust R&D pipeline, Gilead continues to seek breakthroughs in new therapeutic areas.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | January 13 Business Outlook among employees is down by 3.6% over the last month. |
|
Gilead Sciences | January 9 Over the past few months, there has been an downward trend in Web Traffic. |
|
Gilead Sciences | January 5 Job postings are down by 16.7% in the last couple of days. |
|
Gilead Sciences | January 1 Job postings are down by 19.9% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Gilead Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 324 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 378,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 42 | Sign up | Sign up | Sign up |
| Facebook Followers | 28,649 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 28 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 77,712 | Sign up | Sign up | Sign up |
| X Followers | 72,839 | Sign up | Sign up | Sign up |
| X Mentions | 30 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 6,060 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $927,000 | Sign up | Sign up | Sign up |
| Business Outlook | 53 | Sign up | Sign up | Sign up |
| Linkedin Employees | 14,569 | Sign up | Sign up | Sign up |
| NPS | 20 | Sign up | Sign up | Sign up |
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $122.08 |
| Target Price | Sign up |
| Volume | 1,700,000 |
| Market Cap | $150B |
| Year Range | $94.92 - $127.23 |
| Dividend Yield | 2.6% |
| PE Ratio | 18.78 |
| Analyst Rating | 62% buy |
| Industry | Biotechnology |
In the news
 |
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth KnowingJanuary 12 - Yahoo |
 |
Gilead Sciences: From All-Time Highs To Higher HighsJanuary 12 - SeekingAlpha |
 |
UBS and Citi Go Bullish on Gilead Sciences (GILD)January 12 - Yahoo Entertainment |
 |
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 11 - SeekingAlpha |
 |
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company historyJanuary 11 - CNBC |
|
The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery CollaborationJanuary 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 7.77B | 1.57B | 6.2B | 3.05B | 4.58B | 2.470 |
| Q2 '25 | 7.08B | 1.5B | 5.58B | 1.96B | 3.37B | 2.010 |
| Q1 '25 | 6.67B | 1.54B | 5.13B | 1.32B | 2.61B | 1.810 |
| Q4 '24 | 7.57B | 1.58B | 5.99B | 1.78B | 3.11B | 1.900 |
| Q3 '24 | 7.55B | 1.57B | 5.97B | 1.25B | 1.88B | 2.020 |
Insider Transactions View All
| O'Day Daniel Patrick filed to sell 566,698 shares at $124.8. December 30 '25 |
| Dickinson Andrew D filed to sell 153,503 shares at $122. December 16 '25 |
| Mercier Johanna filed to sell 106,221 shares at $122. December 16 '25 |
| Kramer Kelly A. filed to sell 1,339 shares at $127.1. December 1 '25 |
| O'Day Daniel Patrick filed to sell 577,991 shares at $125.9. December 1 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Val Hoyle |
Oct 10, 25 | Sell | $1K - $15K |
| Valerie Hoyle |
Sep 12, 25 | Buy | $1K - $15K |
| Marjorie Taylor Greene |
Jun 19, 25 | Buy | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $150B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 18.78.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $122.08.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 2.6%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.
